Moleculin Biotech, Inc. Contracts & Agreements

Patent and Technology License Agreement dated October 21, 2022 by and between The Board of The University Of Texas System on behalf of The University Of Texas M.D. Anderson Cancer... (Filed With SEC on March 22, 2023)

Portfolio Development Advisor Agreement dated September 6, 2022 between KEWAT, LLC and Moleculin Biotech, Inc (Filed With SEC on November 10, 2022)

Description of Registrant's Securities (Filed With SEC on March 24, 2022)

Patent And Technology License Agreement dated June 29, 2017 by and between The Board of Regents of The University Of Texas System on behalf of The University Of Texas M. D.... (Filed With SEC on March 24, 2022)

Amendment No. 1 to the Patent And Technology License Agreement dated June 29, 2017 by and between The Board of Regents of The University Of Texas System on behalf of The... (Filed With SEC on March 24, 2022)

Patent And Technology License Agreement dated December 2, 2021 by and between The Board of Regents of The University Of Texas System on behalf of The University Of Texas M. D.... (Filed With SEC on March 24, 2022)

Patent And Technology License Agreement dated December 3, 2021 by and between The Board of Regents of The University Of Texas System on behalf of The University Of Texas M. D.... (Filed With SEC on March 24, 2022)

Patent And Technology License Agreement dated February 3, 2022 by and between The Board of Regents of The University Of Texas System on behalf of The University Of Texas M. D.... (Filed With SEC on March 24, 2022)

Amended and Restated Sublicense Agreement dated December 20, 2021, by and between Moleculin Biotech Inc. and WPD Pharmaceuticals (Filed With SEC on December 27, 2021)

Assignment Consent Letter by and between WPD Pharmaceuticals Sp. z o.o and LPC Enterprises, LLC and Moleculin Biotech, Inc (Filed With SEC on December 27, 2021)

Amendment No. 4 to Patent and Technology License Agreement, dated June 15, 2021, between the Parties dated April 2, 2012, as previously amended by Amendment No. 1 dated October... (Filed With SEC on August 11, 2021)

Form of Indemnification Agreement between Moleculin Biotech, Inc. and its officers and directors (Filed With SEC on August 11, 2021)

MOLECULIN BIOTECH, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement (Filed With SEC on June 25, 2021)

PURCHASE AGREEMENT (Filed With SEC on June 25, 2021)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on June 25, 2021)

Description of Registrant's Securities (Filed With SEC on March 24, 2021)

Amended and Restated Sublicense Agreement entered into between the Company and WPD Pharmaceuticals dated March 22, 2021 (Filed With SEC on March 24, 2021)

Underwriting Agreement, dated February 3, 2021, by and between the Company and Oppenheimer & Co. Inc., as representative of the several Underwriters named therein (Filed With SEC on February 4, 2021)

Purchase Agreement (LPC-Moleculin Biotech, Inc.) (Filed With SEC on November 12, 2020)

Registration Rights Agreement(LPC-Moleculin Biotech, Inc.) (Filed With SEC on November 12, 2020)

Amendment No. 3 to Patent and Technology License Agreement between the Parties dated April 2, 2012, dated May 20, 2020, entered into between the Company and the Board of Regents... (Filed With SEC on August 12, 2020)

At Market Issuance Sales Agreement, dated July 17, 2020, by and among the Company and Oppenheimer & Co. Inc (Filed With SEC on July 17, 2020)

Consulting Agreement, dated March 16, 2020, entered into between the Company and Houston Pharmaceuticals, Inc. (HPI) (Filed With SEC on March 19, 2020)

Equipment Lab Letter, dated March 16, 2020, entered into between the Company and Houston Pharmaceuticals, Inc. (HPI) (Filed With SEC on March 19, 2020)

Scientific Advisory Board Agreement, dated (Filed With SEC on March 19, 2020)

MATERIAL TRANSFER AGREEMENT (Filed With SEC on March 17, 2020)

Placement Agency Agreement, dated February 6, 2020, by and between the Company and Oppenheimer & Co. Inc (Filed With SEC on February 6, 2020)

Form of Warrant (Filed With SEC on February 6, 2020)

Form of Placement Agent Warrant (Filed With SEC on February 6, 2020)

Form of Investor Subscription Agreement (Filed With SEC on February 6, 2020)

At Market Issuance Sales Agreement, dated July 23, 2019, by and among the Company and Oppenheimer & Co. Inc (Filed With SEC on July 24, 2019)

Placement Agent Agreement, dated April 23, 2019, by and between the Company and Oppenheimer & Co. Inc (Filed With SEC on April 24, 2019)

Form of Warrant included in Unit (Filed With SEC on April 24, 2019)

Form of Placement Agent Warrant (Filed With SEC on April 24, 2019)

Form of Subscription Agreement (Filed With SEC on April 24, 2019)

Underwriting Agreement, dated March 27, 2019, by and between the Company and Oppenheimer & Co. Inc (Filed With SEC on March 28, 2019)

Form of Warrant included in Unit (Filed With SEC on March 28, 2019)

Form of Underwriter Warrant (Filed With SEC on March 28, 2019)

Sublicense Agreement dated as of February 19, 2019 entered into between the Company and WPD Pharmaceuticals (Filed With SEC on February 21, 2019)

Sublicense Agreement dated as of February 19, 2019 entered into between the Company and Animal Life Sciences, LLC (Filed With SEC on February 21, 2019)

Purchase Agreement, dated as of October 4, 2018, by and between the Company and Lincoln Park Capital Fund, LLC (Filed With SEC on October 5, 2018)

Registration Rights Agreement, dated as of October 4, 2018, by and between the Company and Lincoln Park Capital Fund, LLC (Filed With SEC on October 5, 2018)

Placement Agency Agreement, dated as of June 20, 2018 by and between Moleculin Biotech, Inc. and Roth Capital Partners, LLC (Filed With SEC on June 21, 2018)

Form of Warrant (Filed With SEC on June 21, 2018)

Form of Securities Purchase Agreement (Filed With SEC on June 21, 2018)

Lease Agreement for 5300 Memorial (Filed With SEC on May 14, 2018)

MDA License Agreement (Filed With SEC on May 14, 2018)

Placement Agency Agreement, dated as of February 16, 2018 by and between Moleculin Biotech, Inc. and Roth Capital Partners, LLC (Filed With SEC on February 16, 2018)

Form of Warrant (Filed With SEC on February 16, 2018)

Form of Securities Purchase Agreement (Filed With SEC on February 16, 2018)

At Market Issuance Sales Agreement, dated September 15, 2017, by and among the Company, Roth Capital Partners, LLC and National Securities Corporation (Filed With SEC on September 15, 2017)

IndemnificationAND ADVANCEMENT Agreement (Filed With SEC on May 31, 2017)

3,710,000 SHARES ofCommon Stock, 3,710,000SERIES A Warrants (EXERCISABLE FOR 1,855,000SHARES OF COMMON STOCK), 3,710,000SERIES b Warrants (EXERCISABLE FOR3,710,000 SHARES OF... (Filed With SEC on February 9, 2017)

SERIES [A/B/C] COMMON STOCK PURCHASE WARRANT moleculinbiOtech, inc. (Filed With SEC on February 9, 2017)

____________ SHARES ofCommon Stock, _____________SERIES A Warrants, _____________SERIES b Warrants, and_____________ SERIES c Warrants of MOLECULIN BIOTECH, INC. UNDERWRITING... (Filed With SEC on February 7, 2017)

[FORM OF SERIESA/B/C WARRANT] SERIES[A/B/C] COMMON STOCK PURCHASE WARRANT moleculinbiOtech, inc. (Filed With SEC on February 7, 2017)

WARRANT AGENCYAGREEMENT (Filed With SEC on January 18, 2017)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on October 13, 2016)

CONFIDENTIALGENERAL RELEASE AND SEparation AGREEMENT (Filed With SEC on October 13, 2016)

EMPLOYMENTAGREEMENT (Filed With SEC on August 25, 2016)

PATENT AND TECHNOLOGY DEVELOPMENT ANDLICENSE AGREEMENT (Filed With SEC on April 15, 2016)

ESCROW DEPOSIT AGREEMENT (Filed With SEC on April 15, 2016)

Moleculin Biotech UNDERWRITING AGREEMENT dated [·],2016 Bonwick Capital Partners, LLC (Filed With SEC on March 22, 2016)

MOLECULIN BIOTECH, INC. 2015 STOCK PLAN (Filed With SEC on March 22, 2016)

AnnaMed Rights Transfer Agreement (Filed With SEC on March 22, 2016)

PATENT AND TECHNOLOGY LICENSE AGREEMENT (Filed With SEC on March 22, 2016)

AMENDMENT NO. 1 TO THE PATENT AND TECHNOLOGY LICENSE AGREEMENT (Filed With SEC on March 22, 2016)

PATENT AND TECHNOLOGY LICENSE AGREEMENT (Filed With SEC on March 22, 2016)

AMENDMENT NO. 1 TO THE PATENT AND TECHNOLOGY LICENSE AGREEMENT (Filed With SEC on March 22, 2016)

PATENT AND TECHNOLOGY DEVELOPMENT ANDLICENSE AGREEMENT (Filed With SEC on March 22, 2016)

PATENT AND TECHNOLOGY DEVELOPMENT AND LICENSEAGREEMENT (Filed With SEC on March 22, 2016)

IntertechBio Rights Transfer Agreement (Filed With SEC on March 22, 2016)

AGREEMENT AND PLAN OF MERGER By and Among MOLECULIN BIOTECH, INC. and MOLECULIN, LLC dated as of ____________, 2016 (Filed With SEC on March 22, 2016)

ESCROWDEPOSIT AGREEMENT (Filed With SEC on March 22, 2016)

ESCROWDEPOSIT AGREEMENT (Filed With SEC on February 16, 2016)